Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year, before it entered the second part of a phase 1/2 lymphoma study. The dual-targeting CAR-T, dubbed bbT369, was being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback